

The Global Ophthalmic Drugs Market

<https://marketpublishers.com/r/G68361189D4EN.html>

Date: October 2018

Pages: 104

Price: US\$ 2,750.00 (Single User License)

ID: G68361189D4EN

Abstracts

Ophthalmic Drugs Market – Global Drivers, Restraints, Opportunities, Trends, and Forecast upto2024

Overview: Ophthalmic drugs are widely used for the treatment of eye disorders such as glaucoma, conjunctivitis, cataract, dry eyes, diabetic retinopathy, and others.

Development of innovative ophthalmic drug delivery methods has aided the drug manufacturers in developing effective and advanced therapeutic tactics. American Academy of Ophthalmology has stated that, nearly 11 million individuals in the US are currently suffering with age-related macular degeneration (AMD), while almost 10% of that population have wet AMD. Such inclinations in eye ailments worldwide contribute to the development of the ophthalmic drugs market.

The other significant aspects that help in the improvement of the market are the high pervasiveness of glaucoma globally and intensification in evolution in the development of combination drugs for the glaucoma. Additionally, the changing aspects in the demography worldwide are driving the growth of the market. Nevertheless, hazard of side effects related to ophthalmic drugs and loss of patent for blockbuster drugs are hampering the market growth.

Market Analysis: The “global ophthalmic drugs market” is estimated to witness a CAGR of 6.3% during the forecast period 2018–2024. The global ophthalmic drugs market is analyzed based on indication type and regions.

Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). North America accounts for the largest share of the ophthalmic drugs market, followed by Europe, Asia Pacific, and Rest of the World. North America alone occupies more than 35% of the market, with a significant contribution from the US to the market growth.

Indication Type Analysis: Based on the Indication type, the market is segmented into dry eyes, glaucoma, eye infection/inflammation, retinal disorders, and others. The market is dominated by retinal disorders and is also expected to be the fastest growing segment. However, glaucoma is the second largest segment, owing to the high prevalence of diseases and lack of awareness among the people.

Key Players: Novartis AG, Pfizer, Allergan Inc., Valeant Pharmaceutical International, Santen Pharmaceutical Co., Ltd., Regeneron Pharmaceutical, Akron Inc., and Johnson & Johnson are the key players in the market. Shire Plc, Daiichi Sankyo, Inc., Bayer AG, F.Hoffmann-La Roche, and Sun Pharmaceuticals are the companies to watch for.

Competitive Analysis: In future, several blockbuster drugs that have dominated the morated, are expected to lose their patents. The patents of successful products accounted for over \$6 billion. . Theloss of patent is the most important aspect imposing major threat to the leaders in the ophthalmic drugs market., Lupin Pharmaceuticals received US FDA approval on February 2015, for its bimatoprost ophthalmic solution 0.03%, the generic version of Lumigan. This affected the Allergan's market. Formycon AG, a german biosimilars developing companyis currently developing biosimilar for Eylea by Regeneron Pharmaceutical's. Allergan, meanwhile, is under the threat from Akorn, which is developing a generic version of Restasis. The release of such product is likely to generate an strong burden on the market players.

Benefits: The report provides complete details about the usage and adoption rate of ophthalmic drugs in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player's initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Key Stakeholders:

Contents

1 INDUSTRY OUTLOOK

- 1.1 Industry Overview
 - 1.1.1 Global Driver for Pharmaceutical Demand:
 - 1.1.2 Pharmaceutical Spending Region Wise
 - 1.1.3 R&D Pipeline in Pharmaceutical Industry
 - 1.1.4 Top Pharma Drugs by Sales in 2017 (\$Million)
- 1.2 Industry Trends
- 1.3 Total Addressable Market

2 REPORT OUTLINE

- 2.1 Report Scope
- 2.2 Report Summary
- 2.3 Research Methodology
- 2.4 Report Assumptions

3 MARKET SNAPSHOT

- 3.1 Market Definition – Infoholic Research
- 3.2 Segmented Addressable Market
 - 3.2.1 Trends in the Ophthalmic Drugs Market
- 3.3 Related Markets
 - 3.3.1 Bacterial Conjunctivitis Drugs
 - 3.3.1.1 Trends of Bacterial Conjunctivitis Drugs Market
 - 3.3.2 Contact Lenses
 - 3.3.2.1 Trends of contact lens market

4 MARKET OUTLINE

- 4.1 Ophthalmic Drugs Approved by FDA
- 4.2 Market Segmentation
- 4.3 Porter 5(Five) Forces
- 4.4 PEST Analysis

5 MARKET CHARACTERISTICS

5.1 Market Dynamics

5.1.1 Drivers

5.1.1.1 Increasing prevalence of eye diseases

5.1.1.2 Increasing prevalence of cataract

5.1.1.3 Increasing aging population

5.1.2 Opportunities

5.1.2.1 Increasing mergers & acquisitions

5.1.3 Restraints

5.1.3.1 Complex drug development process

5.1.3.2 Loss of patent for blockbuster drugs

5.2 DRO – Impact Analysis

5.3 Key Stakeholders

6 INDICATION: MARKET SIZE AND ANALYSIS

6.1 Overview

6.2 Dry Eyes

6.3 Glaucoma

6.4 Eye Infection/ Inflammation

6.5 Retinal Disorder

6.6 Others

7 REGIONS: MARKET SIZE AND ANALYSIS

7.1 Overview

7.2 North America

7.2.1 Overview

7.3 Europe

7.3.1 Overview

7.4 Asia Pacific

7.4.1 Overview

7.5 Rest of the World

7.5.1 Overview

8 COMPETITIVE LANDSCAPE

9 VENDOR PROFILES

9.1 Allergan PLC

- 9.1.1 Overview
- 9.1.2 Business Units
- 9.1.3 Geographic Revenue
- 9.1.4 Business Focus
- 9.1.5 SWOT Analysis
- 9.1.6 Business Strategies
- 9.2 Novartis AG
 - 9.2.1 Overview
 - 9.2.2 Business Units
 - 9.2.3 Geographic Presence
 - 9.2.4 Business Focus
 - 9.2.5 SWOT Analysis
 - 9.2.6 Business Strategy
- 9.3 Pfizer Inc.
 - 9.3.1 Overview
 - 9.3.2 Business Units
 - 9.3.3 Geographic Presence
 - 9.3.4 Business Focus
 - 9.3.5 SWOT Analysis
 - 9.3.6 Business Strategies
- 9.4 Valeant Pharmaceuticals International Inc. (Bausch Health)
 - 9.4.1 Overview
 - 9.4.2 Business Units
 - 9.4.3 Geographic Presence
 - 9.4.4 Business Focus
 - 9.4.5 SWOT Analysis
 - 9.4.6 Business Strategy
- 9.5 Santen Pharmaceutical Co., Ltd
 - 9.5.1 Overview
 - 9.5.2 Business Units
 - 9.5.3 Geographic Presence
 - 9.5.4 Business Focus
 - 9.5.5 SWOT Analysis
 - 9.5.6 Business Strategies
- 9.6 Akorn Inc.
 - 9.6.1 Overview
 - 9.6.2 Business Focus
 - 9.6.3 SWOT Analysis
 - 9.6.4 Business Strategy

9.7 Johnson & Johnson

9.7.1 Overview

9.7.2 Business Units

9.7.3 Geographic Revenue

9.7.4 Business Focus

9.7.5 SWOT Analysis

9.7.6 Business Strategies

10 COMPANIES TO WATCH FOR

10.1 Shire plc

10.1.1 Overview

10.1.2 Highlights

10.2 Daiichi Sankyo, Inc.

10.2.1 Overview

10.2.2 Highlights

10.3 Bayer AG

10.3.1 Overview

10.4 F. Hoffmann-La Roche (Genentech)

10.4.1 Overview

10.5 Sun Pharmaceuticals

10.5.1 Overview

10.5.2 Highlights

Annexure

Abbreviations

List Of Tables

LIST OF TABLES

Table 1 NOVARTIS AG: OFFERINGS

Table 2 NOVARTIS AG: RECENT DEVELOPMENTS

Table 3 PFIZER INC.: OFFERINGS

Table 4 PFIZER INC.: RECENT DEVELOPMENTS

Table 5 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: OFFERINGS

Table 6 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: RECENT DEVELOPMENTS

Table 7 SANTEN PHARMACEUTICAL CO., LTD: OFFERINGS

Table 8 SANTEN PHARMACEUTICAL CO., LTD: RECENT DEVELOPMENTS

Table 9 AKORN INC: OFFERINGS

Table 10 AKORN INC.: RECENT DEVELOPMENTS

Table 11 JOHNSON & JOHNSON: PRODUCT OFFERINGS

Table 12 JOHNSON & JOHNSON: RECENT DEVELOPMENTS

Table 13 SHIRE PLC: OVERVIEW

Table 14 SHIRE PLC: RECENT DEVELOPMENTS

Table 15 DAIICHI SANKYO, INC.: RECENT DEVELOPMENTS

Table 16 BAYER AG: OVERVIEW

Table 17 BAYER AG: RECENT DEVELOPMENTS

Table 18 F. HOFFMANN-LA ROCHE: OVERVIEW

Table 19 F. HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS

List Of Charts

LIST OF CHARTS

Chart 1 GLOBAL PHARMACEUTICAL R&D SPENDING (2010–2016)

Chart 2 R&D INVESTMENT BY TOP 10 COMPANIES (\$BN)

Chart 3 CAUSES OF SIGHT LOSS GLOBALLY

Chart 4 RESEARCH METHODOLOGY OF GLOBAL OPHTHALMIC DRUGS MARKET

Chart 5 GLOBAL OPHTHALMIC DRUGS MARKET REVENUE, 2017-2024 (\$MILLION)

Chart 6 OVERVIEW OF GLOBAL CONTACT LENSES USER STATISTICS

Chart 7 OPHTHALMIC DRUGS APPROVED BY FDA DURING 2011–2017

Chart 8 SEGMENTATION OF GLOBAL OPHTHALMIC DRUGS MARKET

Chart 9 PORTER 5 FORCES OF OPHTHALMIC DRUGS MARKET

Chart 10 PEST ANALYSIS OF OPHTHALMIC DRUGS MARKET

Chart 11 MARKET DYNAMICS – DRO ANALYSIS

Chart 12 WORLD POPULATION AGED 65 YEARS AND ABOVE, 1960–2060 (%)

Chart 13 DRO – IMPACT ANALYSIS OF GLOBAL OPHTHALMIC DRUGS MARKET

Chart 14 KEY STAKEHOLDERS

Chart 15 OPHTHALMIC DRUGS MARKET BY PRODUCTS TYPE SEGMENTATION, 2017-2024 (\$MILLION)

Chart 16 OPHTHALMIC DRUGS MARKET REVENUE BY PRODUCTS TYPE, 2017–2024 (\$MILLION)

Chart 17 DRY EYES DRUGS MARKET BY INDICATION SEGMENTATION, 2017-2024 (\$MILLION)

Chart 18 GLAUCOMA DRUGS MARKET BY INDICATION SEGMENTATION, 2017-2024 (\$MILLION)

Chart 19 EYE INFECTION/ INFLAMATION DRUGS MARKET BY TYPES SEGMENTATION, 2017-2024 (\$MILLION)

Chart 20 RETINAL DISORDER DRUGS MARKET BY INDICATION SEGMENTATION, 2017-2024 (\$MILLION)

Chart 21 OTHERS OPHTHALMIC DRUGS MARKET BY INDICATION SEGMENTATION, 2017-2024 (\$MILLION)

Chart 22 OPHTHALMIC DRUGS MARKET BY REGIONAL SEGMENTATION, 2017 VS 2024 (%)

Chart 23 OPHTHALMIC DRUGS MARKET REVENUE BY REGIONS, 2017–2024 (\$MILLION)

Chart 24 OPHTHALMIC DRUGS MARKET REVENUE IN NORTH AMERICA, 2017-2024 (\$MILLION)

Chart 25 OPHTHALMIC DRUGS MARKET REVENUE IN EUROPE, 2017–2024

(\$MILLION)

Chart 26 OPHTHALMIC DRUGS MARKET REVENUE IN ASIA PACIFIC, 2017–2024

(\$MILLION)

Chart 27 OPHTHALMIC DRUGS MARKET REVENUE IN REST OF THE WORLD,
2017–2024 (\$MILLION)

Chart 28 ALLERGAN PLC: OFFERINGS

Chart 29 ALLERGAN PLC: RECENT DEVELOPMENTS

Chart 30 ALLERGAN PLC: OVERVIEW SNAPSHOT

Chart 31 ALLERGAN PLC: BUSINESS UNITS

Chart 32 ALLERGAN PLC: GEOGRAPHIC REVENUE

Chart 33 ALLERGAN PLC: SWOT ANALYSIS

Chart 34 NOVARTIS AG: OVERVIEW SNAPSHOT

Chart 35 NOVARTIS AG: BUSINESS UNITS

Chart 36 NOVARTIS AG: GEOGRAPHICAL PRESENCE

Chart 37 NOVARTIS AG: SWOT ANALYSIS

Chart 38 PFIZER INC.: OVERVIEW SNAPSHOT

Chart 39 PFIZER INC.: BUSINESS UNITS

Chart 40 PFIZER INC.: GEOGRAPHIC PRESENCE

Chart 41 PFIZER INC.: SWOT ANALYSIS

Chart 42 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: OVERVIEW
SNAPSHOT

Chart 43 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: BUSINESS UNITS

Chart 44 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: GEOGRAPHICAL
PRESENCE

Chart 45 VALEANT PHARMACEUTICALS INTERNATIONAL INC.: SWOT ANALYSIS

Chart 46 SANTEN PHARMACEUTICAL CO., LTD: OVERVIEW SNAPSHOT

Chart 47 SANTEN PHARMACEUTICAL CO., LTD: BUSINESS UNITS

Chart 48 SANTEN PHARMACEUTICAL CO., LTD: GEOGRAPHIC PRESENCE

Chart 49 SANTEN PHARMACEUTICAL CO., LTD: SWOT ANALYSIS

Chart 50 AKORN INC.: OVERVIEW SNAPSHOT

Chart 51 AKORN INC.: BUSINESS UNITS

Chart 52 AKORN INC.: SWOT ANALYSIS

Chart 53 JOHNSON & JOHNSON: OVERVIEW SNAPSHOT

Chart 54 JOHNSON & JOHNSON: BUSINESS UNITS

Chart 55 JOHNSON & JOHNSON: GEOGRAPHIC REVENUE

Chart 56 JOHNSON & JOHNSON: SWOT ANALYSIS

Chart 57 SUN PHARMACEUTICALS: OVERVIEW

I would like to order

Product name: The Global Ophthalmic Drugs Market

Product link: <https://marketpublishers.com/r/G68361189D4EN.html>

Price: US\$ 2,750.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G68361189D4EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970